​

Mind Medicine (MindMed) Stock (NASDAQ:MNMD)

OwnershipFinancialsChartTranscripts

Previous Close

$17.18

52W Range

$4.70 - $18.42

50D Avg

$12.71

200D Avg

$9.85

Market Cap

$1.34B

Avg Vol (3M)

$2.53M

Beta

2.62

Div Yield

-

MNMD Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

74

IPO Date

Nov 15, 2016

Website

MNMD Performance

MNMD Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-166.31M$-103.92M$-93.87M
Net Income$-183.79M$-108.68M$-95.73M
EBITDA$-166.31M$-105.87M$-92.57M
Basic EPS$-2.06$-1.54$-2.44
Diluted EPS$-2.06$-0.15$-2.44

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Feb 26, 26 | 4:30 PM
Q3 25Nov 06, 25 | 4:30 PM
Q2 25Jul 31, 25 | 4:30 PM

Peer Comparison

TickerCompany
BBOTBridgeBio Oncology Therapeutics Inc.
TNGXTango Therapeutics, Inc.
URGNUroGen Pharma Ltd.
ANABAnaptysBio, Inc.
NRIXNurix Therapeutics, Inc.
RZLTRezolute, Inc.
KODKodiak Sciences Inc.
XNCRXencor, Inc.
FTREFortrea Holdings Inc.
SVRASavara Inc.